Immuron’s Q3 Revenue Rises 16% to AUD 1.5M; Price Target Boosted to $4.00
Emerging Growth Research raised Immuron's 12-month price target to $4.00 and maintained its Buy-Extended rating after 3Q FY2026 revenue rose 16% year-over-year to AUD 1.5 million. Australian sales climbed 15% in AUD, Canadian revenue surged 82% sequentially, and the clinical pipeline advanced two candidates toward Phase 2 trials.
1. Flash Report Maintains Buy-Extended Rating
A recent flash report upheld Immuron’s Buy-Extended rating and increased its 12-month price target to $4.00 from $3.90. The rating reflects continued confidence in the company’s commercial momentum and clinical progress.
2. Triple-Quarter Revenue Growth
Immuron reported AUD 1.5 million in 3Q FY2026 revenue, a 16% year-over-year gain driven by Travelan® sales. Australian revenue rose 15% in AUD and U.S. sales grew 1% in AUD, while Canadian revenue jumped 82% sequentially through targeted brand initiatives.
3. Clinical Pipeline Advances
The company received clearance to move two key programs—IMM-124E (Travelan®) for travelers’ diarrhea and IMM-529 for C. difficile infections—into Phase 2 trials. Immuron is engaging potential partners to support late-stage development of both candidates.
4. Updated Valuation Drives $4.00 Target
Using an EV/Revenue multiple of 6.22x, the enterprise valuation was pegged at approximately $33.3 million. This valuation underpins the upward revision of the price target, reflecting both commercial traction and pipeline value.